Daiwa Keeps Their Buy Rating on Akeso, Inc. (9926)

TipRanksAug 14 08:27

Guotai Haitong: Alzheimer’s Disease Ushers in a New Era of Disease-Modifying Therapies, with Domestic Companies Demonstrating Strong Competitiveness in Pipeline Development

China's neurodegenerative disease drug market was valued at approximately USD 2.6 billion in 2025 and is projected to reach USD 5.5 billion by 2030, representing a compound annual growth rate (CAGR) of approximately 16.0%, significantly outpacing the global growth rate of 8.1%.

Zhitong FinanceAug 13 16:53

The National Development and Reform Commission (NDRC) convened a symposium on the development of the biopharmaceutical industry at the end of last month.

The Price Cost and Certification Center of the National Development and Reform Commission (NDRC) organized a symposium with selected domestic innovative biopharmaceutical companies on July 30 to gain insights into emerging trends, new challenges, and future development trajectories in the biopharmaceutical industry, and to solicit opinions and suggestions for subsequent research initiatives.

AASTOCKSAug 13 10:59

Summit Therapeutics Says Its Partner Akeso Gets China Approval for Ivonescimab in Squamous NSCLC

Summit Therapeutics (SMMT) partner Akeso has received marketing authorization from China's National Medical Products Administration for ivonescimab plus chemotherapy as a first-line treatment for

MT NewswiresAug 12 21:58

Interest in semiconductor industry research has been overtaken.

Recently, innovative pharmaceuticals have experienced a rebound, significantly boosting market interest in the pharmaceutical and biotechnology sector.

cls.cnAug 11 16:18

Akeso Advances IO2.0 + ADC2.0 Strategy: First Patient Dosed in Phase II Study of TROP2/Nectin-4 Bispecific ADC (AK146D1) Combined With Ivonescimab in Breast Cancer

HONG KONG, Aug. 10, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in a Phase II clinical study (AK146D1-202) evaluating AK146D1

PR NewswireAug 10 12:05